Logo image of CNAT

Conatus Pharmaceutic (CNAT) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:CNAT -

0.556
+0 (+0.18%)
Last: 5/26/2020, 8:04:43 PM
0.54
-0.02 (-2.88%)
After Hours: 5/26/2020, 8:04:43 PM

CNAT Key Statistics, Chart & Performance

Key Statistics
Market Cap18.44M
Revenue(TTM)14.69M
Net Income(TTM)-10.12M
Shares33.17M
Float27.06M
52 Week High1.07
52 Week Low0.23
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-0.34
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
CNAT short term performance overview.The bars show the price performance of CNAT in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

CNAT long term performance overview.The bars show the price performance of CNAT in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20 -25

The current stock price of CNAT is 0.556 null. In the past month the price increased by 61.16%. In the past year, price decreased by -28.02%.

Conatus Pharmaceutic / CNAT Daily stock chart

CNAT Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to CNAT. When comparing the yearly performance of all stocks, CNAT is one of the better performing stocks in the market, outperforming 72.81% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

CNAT Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to CNAT. The financial health of CNAT is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CNAT Financial Highlights

Over the last trailing twelve months CNAT reported a non-GAAP Earnings per Share(EPS) of -0.34. The EPS increased by 42.37% compared to the year before.


Industry RankSector Rank
PM (TTM) -68.87%
ROA -53.86%
ROE N/A
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%38.46%
Sales Q2Q%-100%
EPS 1Y (TTM)42.37%
Revenue 1Y (TTM)-52.41%

CNAT Forecast & Estimates


Analysts
Analysts0
Price TargetN/A
EPS Next Y-2.94%
Revenue Next YearN/A

CNAT Ownership

Ownership
Inst Owners15.2%
Ins Owners5.21%
Short Float %N/A
Short RatioN/A

About CNAT

Company Profile

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.

Company Info

Conatus Pharmaceutic

16745 W. Bernardo Dr. Suite 250

San Diego CA 92127

CEO: Steven J. Mento

Phone: 858-376-2600

Conatus Pharmaceutic / CNAT FAQ

Can you describe the business of Conatus Pharmaceutic?

Conatus Pharmaceuticals, Inc. is a biotechnology company. It is focused on developing and commercializing medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. Conatus Pharmaceuticals, Inc. is headquartered in San Diego, California.


Can you provide the latest stock price for Conatus Pharmaceutic?

The current stock price of CNAT is 0.556 null. The price increased by 0.18% in the last trading session.


Does CNAT stock pay dividends?

CNAT does not pay a dividend.


What is the ChartMill technical and fundamental rating of CNAT stock?

CNAT has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Which stock exchange lists CNAT stock?

CNAT stock is listed on the Nasdaq exchange.


What is the market capitalization of CNAT stock?

Conatus Pharmaceutic (CNAT) has a market capitalization of 18.44M null. This makes CNAT a Nano Cap stock.